Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2019 Results
06 mars 2020 13h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., March 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel...
Constellation Pharmaceuticals to Present at Investor Conferences
26 févr. 2020 09h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
06 janv. 2020 12h33 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
13 déc. 2019 16h05 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10 déc. 2019 21h05 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock
09 déc. 2019 16h18 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASH
09 déc. 2019 10h00 HE
|
Constellation Pharmaceuticals , Inc.
Preliminary data showed continuing signs of activity across a broad range of parameters, suggesting possible disease-modifying effects of CPI-0610In the first-line treatment arm, 12 out of 15 (80%)...
Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASH to Discuss Updated Preliminary Data from the MANIFEST Clinical Trial with CPI-0610
02 déc. 2019 11h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals to Participate in Upcoming Investor Conferences
13 nov. 2019 09h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2019 Financial Results
06 nov. 2019 09h00 HE
|
Constellation Pharmaceuticals , Inc.
First MANIFEST data showing signs of CPI-0610 clinical activity in JAK-inhibitor-naïve myelofibrosis patients Data showing signs of continuing activity in ruxolitinib-refractory or -intolerant...